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Summary 
Receptor-interacting kinase-3 (RIPK3) is an activator of necroptotic cell death, but recent 
work has implicated additional roles for RIPK3 in inflammatory signaling independent of cell death. 
However, while necroptosis has been shown to contribute to antiviral immunity, death-
independent roles for RIPK3 in host defense have not been demonstrated. Using a mouse model 
of West Nile virus (WNV) encephalitis, we show that RIPK3 restricts WNV pathogenesis 
independently of cell death. Ripk3-/- mice exhibited enhanced mortality compared to WT controls, 
while mice lacking the necroptotic effector MLKL, or both MLKL and caspase-8, were unaffected. 
The enhanced susceptibility of Ripk3-/- mice arose from suppressed neuronal chemokine 
expression and decreased central nervous system (CNS) recruitment of T lymphocytes and 
inflammatory myeloid cells, while peripheral immunity remained intact. These data identify 
pleiotropic functions for RIPK3 in the restriction of viral pathogenesis, and implicate RIPK3 as a 
key coordinator of immune responses within the CNS. 
 
 
 
Introduction 
 Necroptosis is a form of programed cell death coordinated by receptor-interacting kinases 
1 (RIPK1) and 3 (RIPK3). Stimuli including death receptor and pattern recognition receptor (PRR) 
ligation induce the activation of RIPK3 and the downstream phosphorylation of mixed lineage 
kinase domain-like protein (MLKL). MLKL serves as an executioner protein, promoting cell death 
via plasma membrane disruption and cell rupture (Cho et al., 2009; Wang et al., 2014a). While 
the molecular mechanisms that orchestrate necroptosis have been the subject of intense 
investigation, the physiological relevance of necroptosis during infection and injury are less well 
defined (Oberst, 2015). Moreover, recent studies have suggested surprising roles for RIPK1 and 
RIPK3 in promoting inflammation independently of cell death signaling, indicating that these 
proteins may serve pleiotropic and context-dependent functions in host immune responses 
(Lawlor et al., 2015; Moriwaki and Chan, 2016; Najjar et al., 2016; Newton et al., 2016). 
 RIPK3 signaling has been implicated in the control of diverse viral infections, including 
influenza A virus (IAV) (Nogusa et al., 2016), Vaccinia virus (Cho et al., 2009; Pan et al., 2014) 
herpes simplex virus-1 (HSV-1) (Huang et al., 2015), and murine cytomegalovirus (MCMV) (Upton 
et al., 2010, 2012). However, evidence of death-independent, RIPK3-mediated control of viral 
infections remains limited. Of note, the involvement of RIPK3 in the restriction of neuroinvasive 
infections is not known, and studies of the role of RIPK3 in defense against potentially 
neuroinvasive viruses such as HSV and CMV have thus far been limited to models of peripheral 
infection.  
 West Nile virus (WNV) is an encephalitic flavivirus of global concern. WNV cycles in nature 
between avian and mosquito reservoirs, with incidental infection of mammals, including humans. 
After peripheral infection, WNV replicates in lymphoid tissues before entering the central nervous 
system (CNS) in a subset of human hosts. Neuroinvasive WNV infection is fatal in many patients, 
while survivors are often left with severe cognitive and neurologic sequelae (Sejvar et al., 2003; 
Vasek et al., 2016). Neuroimmune control of WNV infection requires robust innate immune 
responses among resident CNS cells, as well as recruitment of infiltrating peripheral leukocytes 
(Cho and Diamond, 2012; Daniels and Klein, 2015; Suthar et al., 2013). However, CNS immune 
responses must be carefully regulated, as neural tissue is susceptible to immunologic injury and 
is limited in its capacity for repair (Daniels et al., 2017; Wang et al., 2003). Thus, uncovering the 
mechanisms that promote protective versus pathologic CNS inflammation during neurotropic 
flavivirus infection is critical for the development of targeted treatments, none of which currently 
exist (Kok, 2016).  
 Here, we demonstrate a previously unknown function for RIPK3 in the coordination of 
protective neuroinflammation during WNV infection that is independent of MLKL-driven 
necroptosis. Using a mouse model of WNV encephalitis, we show that mice lacking RIPK3 or the 
kinase activity of RIPK1, but not those lacking MLKL or both MLKL and Caspase-8, exhibit 
enhanced susceptibility to fatal WNV infection. While RIPK3 was dispensable for clearing WNV 
infection in peripheral compartments, Ripk3-/- mice failed to effectively restrict infection within the 
CNS due to decreased recruitment of infiltrating leukocytes. Our studies demonstrate that RIPK3 
promotes neuroinflammation during WNV infection by driving the neuronal expression of 
inflammatory chemokines in a manner that requires its kinase activity and that of RIPK1. These 
findings uncover a critical physiologic function for death-independent, RIPK3-driven inflammation 
in restricting a neurotropic viral infection of significant public health concern. 
 
Results 
RIPK3 restricts WNV infection independent of induction of cell death 
 To assess the role of RIPK3 and MLKL in controlling WNV pathogenesis, we infected 
Ripk3-/-, Mlkl-/-, and age/sex matched controls subcutaneously via footpad with 100pfu of the 
virulent WNV-TX 2002-HC strain, then monitored mice for survival and the development of clinical 
signs of disease. We found Ripk3-/- mice to be highly susceptible to WNV infection, exhibiting 
accelerated and uniform mortality compared to congenic C57BL/6/NJ (B6/N) controls (Figure 1A). 
Increased mortality in Ripk3-/- mice was accompanied by earlier and more severe development of 
clinical signs of disease burden (Figure 1B). In contrast, survival and disease burden in mice 
lacking the necroptotic effector MLKL (Mlkl-/-) were indistinguishable from congenic C57BL/6J 
(B6/J) controls (Figure 1C, Figure S1A). A recent study of IAV pathogenesis found that upon loss 
of MLKL, RIPK3 signaling could alternatively mediate host defense through engagement of 
caspase-8 mediated apoptosis (Nogusa et al., 2016). In contrast, we found that mice lacking both 
MLKL and caspase-8 (Mlkl-/-Casp8-/-) responded similarly to littermate Mlkl-/- Casp8+/+ controls 
upon WNV infection (Figure S1B-C). These data suggested a critical role for RIPK3 in the 
restriction of WNV infection that was, surprisingly, independent of MLKL-dependent programmed 
necrosis or caspase-8-dependent apoptosis. 
 We next assessed whether WNV was capable of inducing RIPK3-dependent cell death in 
myeloid or neuronal cells, two host cell types permissive to WNV infection, by monitoring cell 
death via an IncuCyte imaging platform (Orozco et al., 2014). Infection of bone marrow-derived 
macrophages (BMDMs) with WNV (MOI 0.01) resulted in minimal cell death in both B6/N and 
Ripk3-/- BMDMs that was indistinguishable from death observed in mock-infected controls. 
However, WNV induced substantial cell death in the presence of the pan-caspase inhibitor zVAD 
in B6/N, but not Ripk3-/-, BMDMs (Figure 1D), suggesting that WNV can induce RIPK3-dependent 
necroptosis only under conditions of caspase inhibition. In contrast, infection of primary cerebral 
cortical neuron cultures (MOI 0.001) resulted in modest cell death (Figure 1D). However, this cell 
death was RIPK3-independent, as WNV-induced cell death was similar in both B6/N and Ripk3-/- 
cultures. Instead, WNV-induced neuronal cell death was dependent on caspase activity, as it was 
completely blocked in cultures of both genotypes by zVAD treatment, consistent with prior reports 
demonstrating WNV-induced neuronal apoptosis (Michaelis et al., 2007; Samuel et al., 2007). 
Histopathologic analysis of CNS tissue sections from WT or Ripk3-/- mice 9 days post infection 
(dpi) revealed no evidence for necrotic cell death in the CNS of mice of either genotype (Figure 
S1D). Together, these data indicate that, in key myeloid and CNS cell types targeted by WNV, 
infection alone does not trigger RIPK3-dependent cell death.  Notably, while BMDMs could be 
induced to undergo RIPK3-dependent cell death in response to WNV infection combined with 
caspase inhibition, neurons were resistant to RIPK3-dependent death in these conditions. 
 To further investigate the function of RIPK3 in controlling WNV infection, we measured 
viral burden in key target tissues following subcutaneous inoculation. These studies revealed 
transiently higher viral burden in Ripk3-/- mice in some peripheral compartments, including serum 
(Figure 1E) and spleen (Figure 1F), while viral burden was unchanged in draining inguinal lymph 
nodes (Figure 1G) and kidney (Figure 1H). Despite higher splenic and serum viral loads early 
after infection, Ripk3-/- mice were nevertheless able to control infection in these compartments, 
with viral titers returning to levels observed in B6/N controls by 8 dpi. Peripheral immunity to WNV 
remained intact in Ripk3-/- mice, which were similar to B6/N controls when comparing overall 
numbers and relative frequencies of all T cell and myeloid subsets analyzed in spleens on 8 dpi 
(Figure S2A-C). Moreover, numbers of antigen-specific T cells identified by staining with a 
tetramer displaying the immunodominant WNV peptide Db-NS4B were similar between genotypes 
(Figure S2B). Overall numbers of splenic B cells and serum WNV-neutralizing antibody titers were 
also similar in Ripk3-/- mice compared to WT controls (Figure S2D). Together, these data indicate 
that the increased pathogenesis observed in Ripk3-/- mice after WNV infection was not due to 
impaired peripheral cellular immunity or a failure to control infection in peripheral compartments.  
 
RIPK3 is required for control of WNV burden within the CNS 
In contrast to our observations in peripheral tissues, we observed significantly increased 
viral loads in Ripk3-/- mice across multiple CNS tissues, including cerebral cortex (Figure 2A), 
brainstem (Figure 2B), cerebellum (Figure 2C), and spinal cord (Figure 2D). Unlike peripheral 
viral loads, increased CNS viral burden did not resolve to WT levels in Ripk3-/- mice by 8 dpi. 
Similar to our survival studies, RIPK3-dependent control of tissue viral burden was MLKL-
independent, as WNV titers were indistinguishable in Mlkl-/- mice compared to WT controls in all 
compartments analyzed (Figure S3A-B). Combined with our observation that peripheral immunity 
appears intact in Ripk3-/- mice, this finding indicates that RIPK3 may play a CNS-intrinsic role in 
the control of neuroinvasive WNV infection. 
 To test whether the protective function of RIPK3 was intrinsic to the CNS, we performed 
intracranial inoculation experiments, which allow examination of CNS viral replication kinetics and 
immune responses without possible confounding factors arising from differential neuroinvasion. 
While intracranial WNV infection results in 100% mortality in mice, Ripk3-/- mice exhibited an 
acceleration of this mortality compared to WT controls (Figure 2E). Analysis of viral burden in 
whole brains following intracranial inoculation revealed that WNV titers were similar between 
genotypes early after infection (2 dpi) (Figure 2F), while titers were increased in Ripk3-/- mice 
compared to controls at later time points (4 and 6 dpi), suggesting that enhanced viral burden and 
accelerated mortality in Ripk3-/- mice were not due to early innate control of viral replication. To 
reinforce this conclusion, and to test whether there might be a cell-intrinsic function of RIPK3 in 
controlling viral replication in target CNS cells, we performed multistep growth curve analysis of 
WNV replication in cultured cerebral cortical neurons and cerebellar granule cell (GC) neurons 
(Figure 2G). We observed no detectable difference in viral replication in Ripk3-/- neurons of either 
type. Together, these findings indicate that RIPK3 is required to control WNV infection within the 
CNS, but that its role is not to limit viral replication within neurons.  
 
RIPK3 is required for normal chemokine production in neurons 
 We next questioned whether, in lieu of suppressing viral replication, RIPK3 regulated the 
expression of key inflammatory mediators in neurons during WNV infection. Examination of 
cytokine and chemokine protein levels in supernatants of in vitro B6/N and Ripk3-/- cortical neuron 
cultures infected with WNV revealed no difference in the expression of the inflammatory cytokines 
TNF-α and IL-1β (Figure S4A). In contrast, Ripk3-/- neuronal cultures exhibited decreased 
expression of several chemokines, including CCL2, CCL5, CCL11, CXCL1, CXCL9, and CXCL10 
(Figure 3A; Figure S4B) following WNV infection. As CCL2 and CXCL10 are both important 
regulators of neuroinflammation during WNV infection (Klein et al., 2005; Lim et al., 2011), we 
focused subsequent investigations on these two chemokines. Subsequent qRT-PCR experiments 
in WNV-infected cortical neuron cultures revealed that decreased chemokine expression in Ripk3-
/- cultures was apparent at the mRNA level (Figure 3B), suggesting that RIPK3 promotes the 
transcription of inflammatory chemokines during neuronal WNV infection. 
Activation of RIPK3 can occur downstream of diverse toll-like receptors (TLRs), via both 
TRIF and Myd88-dependent pathways (He et al., 2011; Kaiser et al., 2013). To assess whether 
RIPK3-driven neuronal chemokine expression was unique to WNV infection or if it could be 
triggered by other inflammatory stimuli, we treated primary cortical neuron cultures with the 
synthetic double-stranded RNA analog poly(I:C), a stimulus that activates TLR3 in neurons 
(Cameron et al., 2007). These experiments revealed decreased CCL2 and CXCL10 protein 
(Figure 3C) and mRNA (Figure 3D) expression in Ripk3-/- cultures compared to B6/N controls, 
suggesting that direct PRR stimulation was sufficient to induce RIPK3-dependent chemokine 
expression in the absence of active infection. Notably, we did not observe significant differences 
in poly(I:C)-induced expression of the inflammatory cytokines TNFa and IL-1b in Ripk3-/- neurons 
compared to B6/N controls (Figure S4C), consistent with our findings in WNV-infected neurons. 
Furthermore, we did not observe evidence for RIPK3-dependent cytokine or chemokine 
expression in either BMDMs or cultured microglia following treatment with TLR ligands (Figure 
S4D-E). Together, these findings imply that RIPK3 may have a specific role in the coordination of 
PRR-induced chemokine expression in neuronal lineage cells of the CNS. 
To gain a more general understanding of the role of RIPK3 in coordinating neuronal 
chemokine expression, we assessed whether the kinase activity of RIPK3, or of its interactor 
RIPK1, was involved in chemokine expression downstream of additional TLR agonists, using the 
TLR3 agonist poly(I:C) (Figure 3E), the TLR4 agonist LPS (Figure 3F), and the TLR7 agonist 
CL264 (Figure 3G). To determine if the kinase activity of the RIP kinases was involved, we 
additionally treated neurons with the RIPK3 inhibitor GSK 843 (Mandal et al., 2014) or the RIPK1 
inhibitor Necrostatin-1 (Nec) (Degterev et al., 2008). We found that pharmacological blockade of 
either RIPK1 or RIPK3 resulted in suppressed CCL2 protein expression in WT neuronal cultures 
to levels similar to Ripk3-/- cultures, suggesting that RIPK3-dependent chemokine expression 
downstream of multiple TLRs requires the kinase activity of both RIPK1 and RIPK3. Neither 
inhibitor impacted CCL2 expression in Ripk3-/- cultures, indicating that the effects of these 
inhibitors in WT cultures were specific to blockade of signaling through RIPK3. In contrast, CCL2 
expression following treatment with the pan-caspase inhibitor QVD was not affected in either 
genotype, suggesting that caspase signaling is not involved in RIPK3-driven neuronal chemokine 
expression. Though Necrostatin-1 has been widely used to inhibit RIPK1 kinase activity, off-target 
effects have been reported (Takahashi et al., 2012). We therefore repeated our Necrostatin-1 
experiments using the more specific RIPK1 inhibitor GSK 963 (Berger et al., 2015) and observed 
very similar results (Figure S4F). To further establish a requirement for RIPK1 kinase activity in 
RIPK3-mediated neuronal chemokine expression, we generated neuronal cultures from RIPK1 
kinase-dead knock-in (Ripk1KD/KD) mice (Berger et al., 2014), in which an inactivating point 
mutation has been introduced into the catalytic domain of RIPK1. Ripk1KD/KD neuronal cultures 
exhibited decreased expression of CCL2 and CXCL10 after either WNV infection (Figure 3H) or 
poly(I:C) treatment (Figure 3I). Consistent with a role for the kinase activity of RIPK1 in a 
protective chemokine response during WNV infection, Ripk1KD/KD mice exhibited accelerated and 
uniform mortality (Figure 3J) and more severe clinical symptoms (Figure S4G) compared to B6/J 
controls, similar to those observed in Ripk3-/- mice, after subcutaneous infection with WNV.   
We next sought to confirm a role for RIPK3 in chemokine expression following TLR 
stimulation or WNV infection in neural cells of human origin.  To do this, we tested the effect of 
poly(I:C) or WNV on three separate human neuroblastoma cell lines (Teitz et al., 2000) 
differentiated into neuron-like cells by culture in retinoic acid and brain-derived neurotropic factor 
(BDNF) (Encinas et al., 2000). Upon poly(I:C) treatment or WNV infection, all three of these cell 
lines produced CCL2. This response was significantly reduced in all three cell lines by co-
treatment with GSK 872, an inhibitor of human RIPK3 (Mandal et al., 2014) (Figure S5A). 
Analogous to the results obtained with Ripk3-/- murine neurons, inhibition of RIPK3 did not cause 
cell-intrinsic differences in viral growth kinetics in human neuroblastoma cells, nor did it affect cell 
death following WNV infection (Figure S5B-C). Together, these studies indicate that the kinase 
activity of RIPK1 and RIPK3 is engaged by both TRIF and Myd88-dependent TLR signaling in 
neurons, that this activity drives robust neuronal chemokine expression, and that the kinase 
activity of RIPK1 is required for protective immunity to WNV infection.  
 
Activation of RIPK3 in neurons triggers chemokine production, not cell death 
We next assessed whether direct activation of RIPK3 in the absence of any exogenous 
immune stimulus was sufficient to drive neuronal chemokine expression. To do this, we created 
mice expressing a chimeric RIPK3 protein fused to two copies of FKBPF36V (RIPK3-2xFV). The 
FKBP domains of this fusion protein bind with high affinity to a synthetic homologue of rapamycin 
referred to here as “AP1.” AP1 treatment induces a rapid, FKBP-mediated oligomerization of 
RIPK3-2xFV proteins, leading to the activation of RIPK3 and recruitment of RIPK1 in the absence 
of any endogenous upstream signal (Orozco et al., 2014). For these studies, we generated mice 
expressing the RIPK3-2xFV construct preceded by a lox-stop-lox element and followed by a T2A-
mCherry sequence, driven by the Rosa26 promoter (Figure 4A). These mice were crossed to 
mice expressing Cre recombinase under the ubiquitously expressed Meox2 (Mox2) promoter, 
resulting in Cre-mediated excision of the inserted stop codon (Figure 4B). Transgene expression 
was confirmed in primary murine embryonic fibroblasts (MEFs) via western blot for FKBP (Figure 
4C) and fluorescent immunocytochemical detection of mCherry (Figure 4D). Similar to our 
previous studies using a related construct in NIH-3T3 cells (Orozco et al., 2014; Yatim et al., 
2015), AP1 treatment of RIPK3-2xFV expressing primary MEFs resulted in robust cell death and 
chemokine expression in Mox2-Cre+ cultures (Figure 4E-F), but did not impact cell viability or 
chemokine expression in Mox2-Cre- cultures. Further experiments confirmed both FKBP and 
mCherry expression in primary cortical neurons cultured from RIPK3-2xFV+ Mox2-Cre+ mice 
(Figures 4C and 4G). Strikingly, AP1 treatment of RIPK3-2xFV+ Mox2-Cre+ neurons did not induce 
cell death (Figure 4H). However, AP1 treatment did potently induce chemokine expression in 
RIPK3-2xFV+ Mox2-Cre+ neurons in a manner that required the kinase activity of RIPK3, as the 
RIPK3 inhibitor GSK 843 blocked AP1-mediated neuronal chemokine expression (Figure 4I). We 
previously demonstrated that RIPK3 oligomerization triggers the recruitment and activation of 
RIPK1. Consistent with these findings, and with a role for the kinase activity of RIPK1 in the 
observed chemokine production, we found that co-treatment with the RIPK1 inhibitor Nec1 also 
abrogated AP1-induced chemokine expression in RIPK3-2xFV+ Mox2-Cre+ neurons. These data 
indicate that direct activation of RIPK3 alone is sufficient to induce death-independent chemokine 
expression in neurons.  
 
RIPK3 is required for normal chemokine production in the CNS upon WNV infection 
 To confirm that RIPK3 contributed to CNS chemokine expression in vivo, we analyzed 
brain homogenates from WT and Ripk3-/- mice following either subcutaneous or intracranial WNV 
infection. Consistent with our in vitro results using neuronal cultures, brains of Ripk3-/- mice 
exhibited decreased CCL2 and CXCL10 expression compared to B6/N controls following both 
subcutaneous (Figure 5A) and intracranial (Figure 5B) infection. Additional experiments revealed 
that CCL2 and CXCL10 mRNA levels were similarly decreased in Ripk3-/- brains in both infection 
models (Figure 5C-D). Brains of WNV-infected Ripk3-/- mice exhibited decreased expression of 
additional chemokines, including CCL11, CXCL1, and CXCL9, though the impact of RIPK3 on 
expression of these additional chemokines was variable between infection routes (Figure S6A-
B). In contrast, brains of Mlkl-/- mice exhibited levels of chemokine expression after subcutaneous 
WNV infection that were indistinguishable from B6/J controls (Figure S6C).  
 
RIPK3 coordinates immune cell infiltration into the CNS upon WNV infection 
As mice lacking RIPK3 exhibited diminished expression of leukocyte chemoattractants in 
the CNS during WNV infection, we questioned whether this would result in poor CNS recruitment 
of inflammatory cells. Flow cytometric analysis of leukocytes isolated from whole brains at 8 dpi 
following subcutaneous inoculation revealed significantly decreased recruitment of multiple 
subsets of infiltrating cells in the CNS of Ripk3-/- mice, including CD4+ and CD8+ T cells (Figure 
6A-B). Notably, Ripk3-/- mice were also impaired in their ability to recruit antigen-specific CD8+ T 
cells to the CNS, exhibiting both decreased relative percentages and overall numbers of WNV-
NS4B tetramer+ CD8+ cells (Figure 6C-D). Analysis of infiltrating myeloid cell populations also 
revealed decreased frequencies of infiltrating CD45hi cells among total CD11b+ cells (Figure 6E-
F). While Ripk3-/- mice exhibited decreased numbers of infiltrating CD45hi CD11b+ F4/80+ 
monocytes/macrophages and CD45hi CD11c+ MHCII+ antigen presenting cells, overall numbers of 
CD45lo CD11b+ F4/80+ resident microglia were unaltered, suggesting that decreased myeloid cell 
numbers in the Ripk3-/- CNS are due to impaired recruitment of infiltrating cells and not defects in 
resident immune cell populations. Critically, neither Mlkl-/- nor Mlkl-/-Casp8-/- mice exhibited defects 
in CNS recruitment of any immune cell subset after WNV infection (Figure S7A-B), suggesting 
that programmed cell death does not contribute to RIPK3-mediated neuroinflammation. Together, 
these data indicate that RIPK3 is required to coordinate the recruitment of a wide variety of 
immune cell subsets into the CNS following neuroinvasive WNV infection, and that it does so in 
a cell death-independent manner.  
 
RIPK3 contributes to CNS recruitment of CCR2+ and CXCR3+ infiltrating leukocytes 
 To assess whether decreased CCL2 and CXCL10 expression specifically contributed to 
decreased neuroinflammation in WNV-infected Ripk3-/- mice, we performed additional flow 
cytometric analysis using markers for the CCL2 receptor, CCR2, and the CXCL10 receptor, 
CXCR3. In brain tissues analyzed on day 8 after subcutaneous infection, Ripk3-/- mice exhibited 
decreased percentages of CXCR3+ cells among CD3hi T lymphocytes, as well as decreased 
percentages of CCR2+ cells among CD11b+ myeloid cells compared to WT controls (Figure 7A-
B). Decreased recruitment of CXCR3+ lymphocytes extended to both CD4+ and CD8+ T cell 
subsets (Figure 7C). We also observed decreased numbers of CD45hi CD11b+ F4/80+ CCR2+ 
inflammatory monocytes (Figure 7D). Whole brain homogenates also exhibited decreased mRNA 
expression of both CXCR3 and CCR2 (Figure 7E).  While some of this chemokine receptor 
expression is derived from resident CNS cells, these data support the notion of decreased CXCR3 
and CCR2 expressing infiltrating cells in the brains of Ripk3-/- mice. Ultimately, these findings 
suggest that RIPK3-dependent expression of CXCL10 and CCL2 is necessary for robust 
recruitment of antiviral leukocytes to the CNS during WNV infection.  
   
 
 Discussion 
 Despite their profound and growing burden to global public health, the factors that govern 
pathogenesis and host control of neurotropic infections remain incompletely understood. Here, 
we demonstrate a previously unknown function for RIPK3 in coordinating protective 
neuroinflammation during neuroinvasive West Nile virus infection. Remarkably, RIPK3 restricted 
WNV pathogenesis in a necroptosis-independent manner, as WNV did not induce necroptosis in 
primary neuronal cultures and both MLKL and caspase-8 were dispensable for the protective 
effects of RIPK3 in vivo. While RIPK3 did not directly influence viral replication within neurons, it 
was necessary for robust neuronal chemokine expression and the CNS recruitment of infiltrating 
antiviral leukocytes, an effect that also required the kinase activity of RIPK1. These findings 
identify RIPK3 as a key neuronal regulator of CNS inflammation during flavivirus encephalitis.  
In vivo neuronal expression of RIPK3 has been established by several recent reports and 
appears to contribute to inflammation and pathogenesis in rodent models of cerebral 
ischemia/reperfusion injury (Xu et al., 2016), lysosomal storage disorders (Vitner et al., 2014), 
and traumatic brain injury (Liu et al., 2016). RIPK3 is also expressed in glia, including microglia, 
astrocytes, and oligodendrocytes, where it has been shown to contribute to the pathogenesis of 
rodent and human neurodegeneration, CNS autoimmunity, and demyelination (Ito et al., 2016; 
Ofengeim et al., 2015; Re et al., 2014). While the potential for RIPK3 to induce neuroinflammatory 
pathogenesis has been well established by these prior reports, our study instead demonstrates 
an indispensable, protective role for RIPK3-mediated neuroinflammation and establishes RIPK3 
as a critical host factor in controlling neurotropic viral infection. Our study focused on RIPK3-
dependent effects in neurons, as they are the primary CNS target of WNV and exhibit robust 
chemokine expression during infection (Getts et al., 2008; Klein et al., 2005). While we did not 
observe a requirement for RIPK3 signaling in chemokine production by microglia, our results 
cannot rule out additional roles for this pathway in non-neuronal cells of the CNS. We also note 
efforts that are currently underway to develop RIPK1 inhibitors with activity in the CNS as a 
treatment for neurodegeneration and ischemic injury. Our findings indicate that such compounds 
may also increase susceptibility to neuroinvasive viral infection. 
 A key finding in our study is the contribution of RIPK3 to the chemotactic milieu that 
supports protective antiviral neuroinflammation. Neuronal expression of chemokines has been 
well established to underlie successful antiviral immunity during WNV infection, contributing to 
leukocyte influx and viral clearance (Bardina et al., 2015; Durrant et al., 2015; Klein et al., 2005). 
Beyond the context of infection, CNS chemokines also serve critical roles in CNS homeostasis, 
development, neurotransmission, and repair (Durrant et al., 2014b; Ransohoff and Trettel, 2015; 
Reaux-Le Goazigo et al., 2013; Williams et al., 2014a). Our findings raise the additional possibility 
that RIPK3 may serve previously unknown chemokine-mediated functions in a diverse array of 
neurologic processes.  
 Our study and other reports (Lawlor et al., 2015; Moriwaki and Chan, 2016; Najjar et al., 
2016; Newton et al., 2016; Wang et al., 2014b) demonstrate a capacity for RIPK3 to induce 
inflammation independently of necroptosis. While recent studies have demonstrated a death-
independent role for RIPK3 in NLRP3 inflammasome activation (Lawlor et al., 2015; Wang et al., 
2014b) as well as noncanonical IL-1β processing in myeloid cells (Moriwaki et al., 2015), our 
study did not uncover any impact on IL-1β mRNA or protein expression in Ripk3-/- neuronal 
cultures or brain tissues following WNV infection. Moreover, the phenotype of Ripk3-/- mice 
following WNV infection is markedly different than mice lacking the IL-1 receptor or the 
inflammasome adaptor ASC, which both exhibit elevated CNS chemokine expression and 
enhanced, but not protective, neuroinflammation (Durrant et al., 2014a; Durrant et al., 2013; 
Kumar et al., 2013; Ramos et al., 2012). Thus, death-independent functions for RIPK3 may differ 
significantly by inflammatory stimulus and host cell type.  
Consistent with this idea, we found that in neurons, but not in bone marrow-derived 
myeloid cells or microglia, chemokine expression stimulated by TLR agonists or WNV infection 
required the kinase activity of both RIPK1 and RIPK3. Also consistent with this finding, mice 
expressing a kinase-dead form of RIPK1 displayed increased susceptibility to WNV infection 
similar to that observed in Ripk3-/- mice. We also found that even direct activation of RIPK3 in 
neurons failed to trigger necroptosis, but rather promoted chemokine expression. Further 
molecular mechanisms that govern the functions of RIPK1 and RIPK3 in these contexts remain 
the subject of ongoing investigation, though our study provides some initial insights. For example, 
in contrast with recent reports using cultured myeloid cells (Ito et al., 2016), in neurons we 
observed that the requirement for RIPK1 and RIPK3 kinase activity downstream of TLR ligation 
did not require inhibition of the caspases. While we report an unexpected requirement for RIPK1 
and RIPK3 signaling downstream of TLR ligation in neurons, our findings do not rule out 
engagement of RIPK signaling by other innate immune pathways during WNV infection of these 
cells. Together, our findings indicate an unexpected diversity in the outcomes of RIPK1 and 
RIPK3 signaling between cell types and imply additional obligate functions for this pathway within 
the CNS that are not observed in other tissues.  
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Figure Legends 
 
Figure 1: RIPK3 limits WNV pathogenesis independently of MLKL and cell death.  
(A) Survival analysis in 8 week old Ripk3-/- mice and age/sex matched congenic C57BL/6NJ 
controls (B6/N) following subcutaneous inoculation with 100pfu WNV-TX. N= 9 mice/genotype. 
(B) Presentation of clinical signs of disease in B6/N or Ripk3-/- mice on indicated days following 
subcutaneous WNV infection. N= 9 mice/genotype.  
(C) Survival analysis in 8 week old Mlkl-/- mice and age/sex matched congenic C57BL/6J controls 
(B6/J) following subcutaneous inoculation with 100pfu WNV-TX. N= 15(B6/J) or 13 (Mlkl-/-).  
(D) Kinetics of cell death in primary bone-marrow derived macrophage (BMDM) or cortical neuron 
(CN) cultures after infection with 0.01 (BMDM) or 0.001 (CN) MOI WNV-TX, with or without co-
treatment with the pan-caspase inhibitor zVAD. Cell death was determined by Sytox Green uptake 
and quantified as the percent of total cell nuclei that are Sytox Green-positive. N= 3 (BMDM) or 6 
(CN).  
(E-H) 8 week old B6/N or Ripk3-/- mice were infected subcutaneously with 100 pfu WNV-TX. On 
indicated days following infection, the indicated tissues were harvested, weighed, homogenized, 
and assayed for WNV titers via qRT-PCR (E,G) or plaque assay (F,H). qRT-PCR data are 
normalized against a standard curve of known viral titers to generate plaque-forming unit (pfu) 
equivalents (E,G).  
-**p<0.01, ***p<0.001. Error bars represent SEM. Dotted lines indicate limits of detection. All data 
are pooled from two or three independent experiments. 
See also related figures S1 and S2. 
 
Figure 2: RIPK3 restricts WNV replication in the CNS in a neuron-extrinsic manner.  
(A-D) 8 week old B6/N or Ripk3-/- mice were infected subcutaneously with 100 pfu WNV-TX. On 
indicated days following infection, the indicated tissues were harvested, weighed, homogenized, 
and WNV titers measured via plaque assay. 
(E) Survival analysis in 8 week old Ripk3-/- mice and age/sex matched congenic C57BL/6NJ 
controls (B6/N) following intracranial inoculation with 10pfu WNV-TX. N=6 mice/genotype.  
(F) 8 week old B6/N or Ripk3-/- mice were infected intracranially with 10 pfu WNV-TX. On indicated 
days following infection, whole brains were harvested, weighed, homogenized, and WNV titers 
were measured via plaque assay.  
(G) Multistep viral growth curve analysis in primary B6/N or Ripk3-/- cortical neuron or cerebellar 
granule cell neuron cultures following infection with 0.001 MOI WNV-TX. N= 9 (C) or 6 (D).  
-*p<0.05, **p<0.01, ***p<0.001. Dotted lines indicate limits of detection. All data are pooled from 
two or three independent experiments.  
See also related figure S3. 
 
Figure 3: RIPK3-mediated neuronal chemokine expression occurs downstream of multiple 
TLRs and requires the kinase activity of RIPK1 and RIPK3.  
(A-D) CCL2 or CXCL10 expression in B6/N or Ripk3-/- cortical neuron cultures following infection 
with 0.001 MOI WNV-TX (A-B) or treatment with 1 μg/ml poly(I:C) (C-D), measuring protein in 
supernatant via Bio-plex multiplex immunoassay assay (A,C) or mRNA expression in cells via 
qRT-PCR (B,D). N=3-6 replicates/group.  
(E-G) CCL2 expression measured by ELISA in cortical neuron culture supernatants after 24h 
treatment with 1 μg/ml poly(I:C) (E), 1 μg/ml LPS (F), or 1 μg/ml CL264 (G). Prior to addition of 
TLR agonist, cells were pretreated for 1h with 30 μM Necrostatin-1 (Nec), 100 nM GSK 843, 
and/or 2 μM QVD. Inhibitors remained in culture medium for the duration of the experiment. As 
experiments in (C-E) happened concurrently, data with each TLR agonist is compared against a 
single set of vehicle controls (gray and orange bars), the data for which is repeated in each panel. 
N=4 replicates/group. 
(H-I) CCL2 or CXCL10 expression in B6/J or Ripk1KD/KD cortical neuron cultures following infection 
with 0.001 MOI WNV-TX (H) or treatment with 1 μg/ml poly(I:C) (I), measured via qRT-PCR. N=4 
replicates/group.  
(J) Survival analysis in 8 week old Ripk1KD/KD mice and B6/J controls following subcutaneous 
inoculation with 100pfu WNV-TX. N=7 mice/genotype. 
-*p<0.05, **p<0.01, ***p<0.001. Error bars represent SEM. All data are pooled from at least two 
independent experiments.  
See also related figures S4 and S5. 
 
Figure 4: RIPK3 activation alone is sufficient to drive neuronal chemokine expression 
A) Schematic illustrating the transgene construct and Cre-mediated deletion of the stop cassette 
driving transgene expression. 
(B) DNA gels depicting genotyping strategy for RIPK3-2xFVfl/fl Mox2-Cre+ mice. Top row: presence 
of RIPK3-2xFV transgene; second row: RIPK3-2xFV transgene with deleted stop cassette; third 
row: confirmation of transgene homozygosity by detecting absence of WT Rosa26 locus; fourth 
row: detection of Mox2-Cre expression (smaller bp product). See methods.  
(C) Western blot confirmation of FKBP expression in murine embryonic fibroblast (MEF) and 
cortical neuron cultures. Actin is included as a housekeeping control.  
(D,G) Immunocytochemical detection of mCherry (red) and DAPI (blue) in primary murine 
embryonic fibroblast (MEF) (D) or cortical neuron cultures (G) of the indicated genotype. Images 
are representative of 3 replicates/genotype. Scale bar= 20μm (D) or 40μm (G). 
(E, H) Kinetics of cell death in primary RIPK3-2xFVfl/fl Mox2-Cre+ primary MEF (E) or cortical 
neuron cultures (H) after treatment with 100nM AP1 in the presence of indicated inhibitors. 
Combined treatment with TNF-α and cycloheximide served as a positive control for cell death (H). 
Cell death was determined by Sytox Green uptake and quantified as the percent of total cell nuclei 
that are Sytox Green-positive. N= 2-4 replicates/group.  
(F, I) CCL2 expression measured by ELISA in supernatants of RIPK3-2xFVfl/fl MEF (F) or cortical 
neuron (I) cultures of indicated genotype 24h after treatment with AP1 and/or indicated inhibitors. 
N= 3 replicates/group. 
***p<0.001. Error bars represent SEM. All data are pooled from at least two independent 
experiments.  
 
Figure 5: RIPK3 enhances CNS chemokine expression after WNV infection.  
(A-B) CCL2 (left) or CXCL10 (right) protein expression as determined by Bio-plex protein 
immunoassay in clarified brain homogenates taken on indicated days after either intracranial (A) 
or subcutaneous (B) WNV infection.  
(C-D) CCL2 (left) or CXCL10 (right) mRNA expression as determined by qRT-PCR using RNA 
extracted from whole brains taken on indicated days after either intracranial (C) or subcutaneous 
(D) WNV infection. Data are expressed as ΔΔCT, wherein CT values for individual samples are 
first normalized to the housekeeping gene Gapdh, then normalized against values for uninfected 
controls.  
-*p<0.05, **p<0.01, ***p<0.001. Error bars represent SEM. N=6 for all panels. Data are pooled 
from two independent experiments.  
See also related figure S6. 
 
Figure 6: RIPK3 coordinates CNS immune cell infiltration after WNV infection.  
(A-F) Total brain leukocytes were isolated from B6/N or Ripk3-/- mice on day 8 following 
subcutaneous inoculation with WNV-TX. 
(A) Representative flow cytometric plots showing CD4+ and CD8+ T cells among total brain 
leukocytes. Numbers represent percentage of cells in each gate relative to total plotted cells.  
(B) Percentage (top row) and numbers (bottom row) of CD4+ and CD8+ T cells among total brain 
leukocytes.  
(C) Representative plots showing cells stained with a tetramer displaying the immunodominant 
WNV peptide Db-NS4B (NS4B) after prior gating for CD3hi and CD8+ cells.  
(D) Percentage of NS4B tetramer+ cells among total CD8+ T cells (top) or total number of CD8+ 
NS4B+ T cells collected from total brain leukocytes (bottom).  
(E) Representative plots showing CD45lo vs. CD45hi expressing cells after prior gating for CD11b+ 
cells.  
(F) Percentage of CD45hi cells among total CD11b+ cells (top left) or total numbers of cells 
expressing indicated markers collected from total brain leukocytes (top right and bottom row).  
-*p<0.05, **p<0.01, ***p<0.001. Data are pooled from two or three independent experiments.  
See also related figure S7. 
 
Figure 7: RIPK3 mediates CNS recruitment of CXCR3+ and CCR2+ infiltrating leukocytes. 
(A-F) Total brain leukocytes were isolated from B6/N or Ripk3-/- mice on day 8 following 
subcutaneous inoculation with WNV-TX. 
(A) Representative flow cytometric plots showing CXCR3+ cells after prior gating for CD3- or CD3+ 
cells (left) or CCR2+ cells after prior gating for CD11b+ cells. Numbers represent percentage of 
cells in each gate relative to total plotted cells. 
(B) Percentages of CXCR3+ cells among total CD3hi cells (top) or CCR2+ cells among total CD11b+ 
cells (bottom).  
(C-D) Total numbers of cells expressing indicated markers collected from total brain leukocytes.  
(E) qRT-PCR analysis of CXCR3 or CCR2 expression using RNA extracted from whole brains on 
day 8 following subcutaneous WNV infection.  
-**p<0.01, ***p<0.001. All data are pooled from two independent experiments.  
 
Supplemental Information 
 
Figure S1: (Related to Figure 1) WNV disease burden is unaffected by loss of MLKL or 
MLKL and caspase-8. 
(A) 8 week old Mlkl-/- and age/sex matched congenic C57BL/6J (B6/J) controls were infected 
subcutaneously with 100pfu WNV-TX and monitored daily for the presentation of clinical signs of 
disease. N= 15(B6/J) or 13 (Mlkl-/-).  
(B-C) 8 week old Mlkl-/- Casp8-/- or Mlkl-/- Casp8+/+ littermate controls were infected subcutaneously 
with 100pfu WNV-TX and monitored daily for survival (B) and the presentation of clinical signs of 
disease (C). N= 6 mice/genotype.  
(D) Representative 10x images of H&E stained sections of cerebral cortex taken from mice on 
day 9 following subcutaneous WNV infection. Scale bar= 250 μm. Images are representative of 
5 mice/genotype. 
-All data are pooled from two or three independent experiments. 
 
Figure S2: (Related to Figure 1) Peripheral immunity is intact in WNV-infected Ripk3-/- mice. 
(A-D) Splenocytes were harvested from whole spleens on day 8 following subcutaneous WNV 
infection.  
(A) Representative flow plots showing percentages of CD4+ and CD8+ cells out of total 
splenocytes (left column) or WNV-specific, NS4B tetramer+ cells out of total CD8+ cells (right 
column).  
(B-C) Total numbers of cells expressing indicated markers isolated from total splenocytes.  
(D) Total number of B220+ cells isolated from total splenocytes (left). Neutralizing antibody titers 
in serum collected on indicated day after subcutaneous WNV infection were determined by plaque 
reduction neutralization test (PRNT, right). Data are reported as Log10 of the minimum dilution of 
whole serum that results in 50% reduction in plaque forming capacity of a standardized titer of 
WNV (see methods).  
-All data are pooled from two independent experiments. 
 
Figure S3: (Related to Figure 2) MLKL is dispensable for control of WNV infection in 
multiple tissue compartments. 
(A-B) 8 week old Mlkl-/- and age/sex matched congenic C57BL/6J (B6/J) controls were infected 
subcutaneously with 100pfu WNV-TX. On indicated days after infection, the indicated tissues 
were harvested, weighed, homogenized, and WNV titers wre measured via plaque assay. N=6 
mice/genotype.  
-Dotted lines represent limit of detection. All data are pooled from 2 independent experiments.  
 
Figure S4: (Related to Figure 3) Inflammatory cytokine and chemokine expression in 
neuron and macrophage cultures after WNV infection or poly(I:C) treatment 
(A-D) The indicated cytokines or chemokines were analyzed via Bio-Plex Immunoassay (pg/ml) 
or qRT-PCR (ΔΔCT). 
(A-B) Primary cortical neuron cultures were infected with 0.001 MOI WNV-TX. N=3-6 
replicates/group. 
(C-D) Primary cortical neuron (C) or BMDM (D) cultures were treated with 1 μg/ml poly(I:C). N=4 
replicates/group.  
E) CCL2 expression measured by ELISA in primary microglial culture supernatants after 24h 
treatment with 1 μg/ml poly(I:C) or 1 μg/ml CL264. Prior to addition of TLR agonist, cells were 
pretreated for 1h with 100nM GSK 963, 100nM GSK 843, and/or 2 μM QVD. Inhibitors remained 
in culture medium for the duration of the experiment. 
F) CCL2 expression measured by ELISA in cortical neuron culture supernatants after 24h 
treatment with 1 μg/ml poly(I:C), 1 μg/ml LPS, or 1 μg/ml CL264. Prior to addition of TLR agonist, 
cells were pretreated for 1h with 100nM GSK 963. Inhibitor remained in culture medium for the 
duration of the experiment. 
(G) Presentation of clinical signs of disease in B6/J or Ripk1KD/KD mice on indicated days following 
subcutaneous WNV infection. N= 7 mice/genotype.  
-***p<0.001. Error bars represent SEM. All data are pooled from 2-3 independent experiments.  
 
Figure S5: (Related to Figure 3) Chemokine expression, viral replication, and cell death in 
differentiated human neuroblastoma cell lines following WNV infection or (polyI:C) 
treatment.  
(A) CCL2 expression measured by ELISA in supernatants of differentiated human neuroblastoma 
cell line (NB8, NB15, NB16) culture supernatants after 24h treatment with 1 μg/ml poly(I:C) or 
WNV infection (0.001 MOI). Cultures were pretreated with an inhibitor of human RIPK3 (GSK 872, 
100nM) for 1h. Inhibitor remained in culture medium for the duration of the experiment.   
(B) Multistep viral growth curve analysis in neuroblastoma cell lines following infection with 0.001 
MOI WNV, with or without co-treatment with GSK 872. Viral titers were determined by standard 
plaque assay.  
(C) Kinetics of cell death in differentiated human neuroblastoma cell lines after infection with 0.001 
MOI WNV, with or without co-treatment with GSK 872. Cell death was determined by Sytox Green 
uptake and quantified as the percent of total cell nuclei that are Sytox Green-positive. 
-*p<0.05, ***p<0.001. Error bars represent SEM. N=3 for all panels. 
 
 
Figure S6: (Related to Figure 5) CNS chemokine expression in vivo following intracranial 
or subcutaneous WNV infection 
(A-B) 8 week old Ripk3-/- and B6/N controls were infected with WNV-TX, either with 10 pfu 
intracranially (A) or 100 pfu subcutaneously (B). Whole brains were harvested on indicated days 
after infection and clarified homogenates were assayed for chemokine expression via Bio-Plex 
Immunoassay. N=6 mice/genotype. 
(C) 8 week old Mlkl-/- and B6/J controls were subcutaneously infected with WNV-TX. CCL2 and 
CXCL10 mRNA was measured on indicated days after infection in whole brain homogenates via 
qRT-PCR (ΔΔCT). N=6 mice/genotype.  
-*p<0.05. Error bars represent SEM. All data are pooled from two independent experiments.  
 
Figure S7: (Related to Figure 6) CNS immune cell infiltration is unchanged in Mlkl-/- and 
Mlkl-/- Casp8-/- mice following subcutaneous WNV infection.  
(A-B) Total brain leukocytes were isolated from 8 week old mice of indicated genotypes on day 8 
after subcutaneous WNV infection. Graphs represent total numbers of indicated cell populations 
isolated from whole brains. All data are pooled from two independent experiments.  
STAR Methods 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and 
will be fulfilled by the lead contact, Andrew Oberst (oberst@uw.edu).  
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Mice 
Ripk3-/- (Newton et al., 2004), Mlkl-/- (Murphy et al., 2013), Casp8-/- (Beisner et al., 2005), 
Mlkl-/-Casp8-/-, RIPK1KD/KD (Berger et al., 2014), and RIPK3-2xFVfl/fl Mox2-Cre+ mice in this study 
were bred and housed under specific-pathogen free conditions at the University of Washington. 
Wild-type C57BL/6NJ and C57BL/6J controls were either obtained commercially (Jackson 
Laboratories) or bred in-house. Ripk3-/- animals were congenic to the C57BL/6NJ background, 
while all other strains were on the C57BL/6J background; in all cases wild-type controls of 
appropriate sub-strain were used. Mox2-Cre+ mice were obtained commercially (Jackson 
Laboratories, strain 003755) and maintained at hemizygosity. RIPK3-2xFVfl/- mice were produced 
for the authors by inGenious Targeting Laboratory (Rankonkoma, NY). 
 RIPK3-2xFVfl/fl mice were generated using a vector containing a FLAG tag, followed by a 
chimeric version of RIPK3 fused to two copies of FKBPF36V (RIPK3-2xFV), followed by a T2A-
mCherry sequence (Figure S5A). This entire sequence was cloned into the MluI site of a ROSA26-
stop backbone vector using conventional cloning methods. The stop cassette in the ROSA-stop 
backbone vector contains a splice acceptor and a stop cassette flanked by lox-p sites and is 
inserted in intron 1 of the Rosa26 locus. The FLAG-RIPK3-T2A-mCherry sequence is inserted 
immediately downstream of the stop cassette. 
 Genotyping of the RIPK3-2xFV transgene and confirmation of a deleted stop cassette was 
accomplished using multiple PCR reactions (Figure 4B). Two separate reactions were used to 
detect the presence of the RIPK3-2xFV transgene (349bp product) and the transgene with a 
deleted stop cassette (603bp product). Homozygosity of the transgene was assessed by 
confirming the absence of a WT Rosa26 locus (346bp product). Mox2-Cre expression was 
confirmed by the presence of a mutant (300bp) product as compared to a WT (410bp) product. 
See Table S1 for primer sequences. PCR reactions were performed with EconoTaq reagents 
(Lucigen) using genomic DNA extracted from ear tissue according to standard protocols.  
Cell culture and infections 
Primary macrophage cultures were generated from bone marrow via differentiation in 40 
ng/ml M-CSF, as described (Samuel et al., 2006). Embryonic fibroblasts were generated and 
maintained as previously described (Szretter et al., 2012). Primary cultures of cerebral cortical 
neurons and purified cerebellar granule cell neurons were generated using E15 embryos or P3 
neonatal mice, as described (Klein et al., 2005). Purified microglia were obtained from mixed glial 
cultures generated from P1-P3 neonatal mice as described (Williams et al., 2014b). Human 
neuroblastoma cell lines NB8, NB15, NB16 were maintained in a 1:1 mixture of DMEM and Ham’s 
F-12 Nutrient Mix (ThermoFisher). Neuroblastoma cells were differentiated into neuron-like cells 
by supplementing culture medium with 10μM all-trans retinoic acid (Sigma-Aldrich) and 50ng/ml 
recombinant human BDNF (Peprotech), as described (Encinas et al., 2000). For infection 
experiments, macrophage and cultures were infected at MOI 0.01, while primary neuronal 
cultures and neuroblastoma cell lines were infected at MOI 0.001.  
Virus and virologic assays 
WNV strain TX 2002-HC (WNV-TX) was plaque purified as described (Keller et al., 2006) 
and passaged twice through mycoplasma-free Vero cells. Viral stock titers, as well as titers from 
experimental tissues and culture supernatants, were determined by plaque assay on BHK21-15 
cells or qRT-PCR using WNV positive strand-specific primers (Brien et al., 2013). Anti-WNV 
neutralizing antibodies in serum were measured using a plaque reduction neutralization assay as 
previously described (Diamond et al., 2003).  
 
METHOD DETAILS 
Mouse infections 
Subcutaneous WNV infection was performed by injection of 100 pfu WNV-TX in 50 μl of 
HBSS into a rear footpad. For intracranial infection, 10 pfu WNV-TX was injected in 10 μl of HBSS 
into the third cerebral ventricle with a guided 29G needle. Infected mice were monitored daily for 
weight loss and presentation of clinical signs of disease, including hunched posture, ruffled fur, 
hindlimb weakness, and paresis. Severity of paresis was defined as follows: mild – partial loss of 
motor function in one hind limb; moderate – complete or nearly complete loss of motor function in 
one hind limb or partial loss of motor function in both hind limbs; severe – complete or nearly 
complete loss of motor function in both hind limbs and/or pronounced ataxia. Mice reaching a 
moribund state or losing more than 20% of initial body weight were euthanized. All experiments 
were performed in both male and female 8 week old mice, in accordance with protocols approved 
by the University of Washington Animal Care and Use Committee (IACUC).  
Cell death assays 
 Cell death was analyzed using a 2-color IncuCyte Zoom in-incubator imaging system 
(Essen Biosciences), as previously described (Gutierrez et al., 2017; Orozco et al., 2014). Briefly, 
dead cells were detected by measuring uptake of the cell impermeable dye Sytox Green (Life 
Technologies). Cell death was quantified as a percent of Sytox+ cell nuclei out of total cell nuclei 
(Syto Green+) in culture.  
Tissue preparation and CNS leukocyte isolation 
 All tissues harvested from mice for subsequent qRT-PCR, protein, virologic, or flow 
cytometric analysis were extracted following extensive cardiac perfusion with 30 ml of sterile PBS. 
Extracted tissues were weighed and homogenized using 1.0 mm diameter zirconia/silica beads 
(Biospec) in sterile PBS (protein and/or virologic analysis) or RA1 lysis buffer (for RNA isolation, 
Macherey-Nagel). For histological studies, tissues were fixed, sectioned, and stained as 
described (Graham et al., 2015). For flow cytometry, leukocytes were isolated from whole brains 
after digestion in 0.05% collagenase A (Sigma-Aldrich) and 10 μg/ml DNase I (Sigma-Aldrich), 
then purified via centrifugation in 37% isotonic Percoll (Sigma-Aldrich) as described (Szretter et 
al., 2012). 
Flow cytometry 
 Isolated leukocytes from spleens or brains were stained as described (Durrant et al., 
2014a) with fluorescently conjugated antibodies to CD3 (BD, clone 145-2C11), CD4 (BD, clone 
RM4-5), CD8a (BD, clone 53-6.7), CD11b (BD, clone M1/70), CD11c (BD, clone 565451), CD45.2 
(BD, clone 104), CXCR3 (BD, clone CXCR3-173), CCR2 (BD, clone FAB5538A), B220 (BD, clone 
RA3-682), MHCII (BD, clone M5/114.15.2), F4/80 (BD, clone T45-2342), and Db-NS4B tetramer 
(NIH tetramer core facility). Data collection and analysis were performed using an LSR II Flow 
Cytometer (BD) and FlowJo software (Treestar).    
RNA isolation and qRT-PCR 
 Viral RNA in serum was isolated using a Viral RNA Mini Kit (Qiagen). Total RNA from 
tissues and cell cultures was isolated using a Nucleospin RNA Kit (Macherey-Nagel). cDNA was 
synthesized using oligo(dT) random hexamers and SuperScript III Reverse Transcriptase (Life 
Technologies). Fluorogenic quantitative reverse transcriptase PCR (qRT-PCR) analysis was 
performed with previously published oligonucleotide primers (Daniels et al., 2017) (Table S1) 
using Sybr Green reagents and a ViiA 7 Real-Time PCR System (Applied Biosystems). Cycle 
threshold (CT) values for analyzed cytokine/chemokine genes were normalized to CT values of 
the housekeeping gene Gapdh (CTTarget – CTGapdh = ΔCT) Data were subsequently normalized to 
baseline control values (ΔCTexperimental – ΔCTcontrol = ΔΔCT. Viral transcript data were normalized 
against a standard curve of known viral titers to generate pfu-equivalent values (Brien et al., 
2013).  
Protein Analysis 
 Cytokine and chemokine expression in cell culture supernatants or clarified brain 
homogenates were measured using a Bio-Plex multiplex mouse cytokine, chemokine, and growth 
factor multiplex immunoassay and a Bio-Plex 200 (Bio-Rad) instrument according to 
manufacturer’s instructions. CCL2 expression in experiments represented in Figure 7C-E was 
measured using a CCL2 ELISA Ready-SET-Go kit (eBioscience) and a Synergy™ H1 microplate 
reader using Gen5™ software (BioTek Instruments, Inc.). 
Western Blot 
 Cells were lysed in NP40 lysis buffer (150mM NaCl, 20mM Tris-Cl, 1mM EDTA, 1% NP40 
at pH 7.5) containing 1X HaltTM Protease Inhibitor Cocktail (ThermoFisher). Thirty μg of protein 
were run on a 4-12% NovexTM Tris-Glycine mini gel (Fisher Scientific) at 100V for 2.5 hours in WB 
running buffer (24mM tris, 32mM Glycine, 3.5mM SDS) and transferred onto PVDF membrane 
(ThermoFisher) at 300mAmps for 50 min in transfer buffer (6mM tris, 8mM glycine). Membrane 
was blocked in 5% reconstituted dry milk in TBS+1% Tween-20 (TBS-T) for 1 hour. Membranes 
were stained overnight at 4C with primary anti-FKBP (ThermoFisher PA1-026A) and anti-actin 
(Millipore MAP1501) antibodies in 1% milk in TBS-T. Membranes were then stained with HRP-
conjugated secondary antibodies (Santa Cruz sc-2003) for 1h at room temperature. Membranes 
were developed on film after treating with Pierce ECL Western Blotting Substrate (Pierce). 
Immunocytochemistry 
 Fluorescent immunocytochemistry was performed as described (Daniels et al., 2014). 
Cells were fixed for 10 minutes with 4% paraformaldehyde, permeabilized with 0.1% Triton-X, 
and blocked with 10% goat serum. Cells were stained using a primary anti-mCherry antibody 
(Rockland) for 1 hour and goat anti-rabbit AlexaFluor 594 secondary antibody (ThermoFisher) for 
15 minutes, both at room temperature. Nuclei were visualized via staining with DAPI 
(ThermoFisher).  
PRR ligands and chemical agents 
 The following PRR ligands and chemical inhibitors were used in cell culture experiments: 
Poly(I:C) (1 μg/ml, Millipore), LPS-EB Ultrapure (1 μg/ml, Invivogen), CL264 (1 μg/ml, Invivogen), 
zVAD (50 μM, SM Biochemicals), necrostatin-1 (30 μM, Sigma), GSK 963 (100nM, 
GlaxoSmithKline), GSK 843 (100nM, GlaxoSmithKline) (Mandal et al., 2014), GSK 872 (100nM, 
GlaxoSmithKline) and QVD (20 μM, SM Biochemicals), AP1 (100 nM, ClonTech, sold as “BB 
Homodimerizer”).  
QUANTIFICATION AND STATISTICAL ANALYSIS 
 Survival experiments were analyzed via log-rank test. WNV titers in mouse tissues were 
analyzed via nonparametric Mann-Whitney U test. All other experiments were compared with 
parametric tests, including 2-tailed student’s t-test or 2-way ANOVA, with corrections for repeated 
measures, where appropriate. A p value <0.05 was considered statistically significant for all 
comparisons. Statistical parameters for individual experiments can be found within the figure 
legends. All statistical analyses were performed using GraphPad Prism software.  
ADDITIONAL RESOURCES 
The following resources were used under material transfer agreement (MTA): Mlkl-/- mice 
(Walter and Elizabeth Hall Institute, Australia), Casp8-/- mice (University of California, San Diego), 
Ripk3-/- mice (GlaxoSmithKline), Ripk1KD/KD mice (GlaxoSmithKline), GSK inhibitors 
(GlaxoSmithKline), neuroblastoma cell lines NB8, NB15, and NB16 (St. Jude Children’s Research 
Hospital).  
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